Oncology/Hematology
Lung Cancer
More in Lung Cancer
EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy
Actual rates for 2021 lagged behind projections
News, features, and commentary about cancer-related issues
Cancer patients with cachexia added needed pounds with GDF-15 antibody
News, features, and commentary about cancer-related issues
Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan
However, plinabulin plus docetaxel still "not ready for prime time," expert says
Absolute improvement of almost 30%, doubling of duration of response with savolitinib
Two-trial analysis shows about a 40% decreased risk of disease recurrence or death
Novel agent nearly halved risk of progression as first-line therapy in phase III trial
Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy
News, features, and commentary about cancer-related issues
In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity
Alternate criteria based on years of smoking has higher sensitivity and specificity, study says
